Neuroprotection by the Immunomodulatory Drug Pomalidomide in the

Drosophila LRRK2 Parkinson drug repurposing immunomodulation neuroprotection repositioning

Journal

Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824

Informations de publication

Date de publication:
2020
Historique:
received: 20 11 2019
accepted: 03 02 2020
entrez: 3 3 2020
pubmed: 3 3 2020
medline: 3 3 2020
Statut: epublish

Résumé

The search for new disease-modifying drugs for Parkinson's disease (PD) is a slow and highly expensive process, and the repurposing of drugs already approved for different medical indications is becoming a compelling alternative option for researchers. Genetic variables represent a predisposing factor to the disease and mutations in leucine-rich repeat kinase 2 (LRRK2) locus have been correlated to late-onset autosomal-dominant PD. The common fruit fly

Identifiants

pubmed: 32116655
doi: 10.3389/fnagi.2020.00031
pmc: PMC7031158
doi:

Types de publication

Journal Article

Langues

eng

Pagination

31

Informations de copyright

Copyright © 2020 Casu, Mocci, Isola, Pisanu, Boi, Mulas, Greig, Setzu and Carta.

Références

Open Biochem J. 2011;5:37-44
pubmed: 21792375
Front Mol Neurosci. 2014 May 27;7:49
pubmed: 24904275
Am J Med Genet B Neuropsychiatr Genet. 2009 Oct 5;150B(7):1022-3
pubmed: 19152345
Microsc Res Tech. 1999 Apr 15;45(2):106-21
pubmed: 10332728
JAMA Neurol. 2018 Nov 1;75(11):1416-1422
pubmed: 30039155
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12703-8
pubmed: 23858438
Cell Rep. 2019 Feb 12;26(7):1774-1786.e4
pubmed: 30759389
Annu Rev Genet. 2005;39:153-71
pubmed: 16285856
J Parkinsons Dis. 2013 Jan 1;3(3):231-9
pubmed: 24018336
Prog Brain Res. 2010;184:325-41
pubmed: 20887883
Cancer Chemother Pharmacol. 2019 Nov;84(5):1073-1087
pubmed: 31493176
Blood Cancer J. 2013 Sep 06;3:e143
pubmed: 24013664
Biochem Soc Trans. 2019 Apr 30;47(2):651-661
pubmed: 30837320
Genome Biol Evol. 2014 Feb;6(2):273-89
pubmed: 24443439
Neurochem Res. 2017 Feb;42(2):686-696
pubmed: 27943027
Lancet. 2004 May 29;363(9423):1802-11
pubmed: 15172781
Front Neurol. 2018 Oct 15;9:860
pubmed: 30459700
J Exp Med. 1993 Jun 1;177(6):1675-80
pubmed: 8496685
J Neural Transm (Vienna). 2011 May;118(5):795-808
pubmed: 21552986
Onco Targets Ther. 2013 May 10;6:531-8
pubmed: 23690693
PLoS One. 2011;6(6):e21519
pubmed: 21738687
J Neurosci Res. 2013 May;91(5):671-80
pubmed: 23404341
Semin Immunol. 2014 Jun;26(3):267-74
pubmed: 24981286
Neuron. 2006 Mar 16;49(6):833-44
pubmed: 16543132
Mov Disord. 2019 Dec;34(12):1818-1830
pubmed: 31335998
Front Neurosci. 2010 Dec 08;4:205
pubmed: 21165178
J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):223-36; discussion 222
pubmed: 11983801
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2693-8
pubmed: 18258746
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28716886
Curr Opin Neurobiol. 2002 Dec;12(6):633-8
pubmed: 12490252
Biochem Soc Trans. 2012 Oct;40(5):1047-51
pubmed: 22988863
Int J Mol Sci. 2018 Oct 19;19(10):
pubmed: 30347766
Neurol Sci. 2014 Oct;35(10):1495-504
pubmed: 25027012
Curr Biol. 2002 Jul 23;12(14):1263-8
pubmed: 12176339
Biochem Soc Trans. 2012 Oct;40(5):1086-9
pubmed: 22988870
Neural Regen Res. 2018 Sep;13(9):1493-1506
pubmed: 30127102
J Immunol. 2010 Nov 1;185(9):5577-85
pubmed: 20921534
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Br J Haematol. 2020 Feb;188(4):483-485
pubmed: 31566715
PLoS One. 2016 Jan 04;11(1):e0146140
pubmed: 26727265
Mol Neurodegener. 2016 Dec 7;11(1):73
pubmed: 27927216
Oncotarget. 2016 May 31;7(22):33237-45
pubmed: 27120781
Curr Top Dev Biol. 2017;121:173-200
pubmed: 28057299
Cell Transplant. 2019 Apr;28(4):439-450
pubmed: 31094216
Front Neural Circuits. 2009 Jul 01;3:5
pubmed: 19597562
J Exp Med. 1991 Mar 1;173(3):699-703
pubmed: 1997652
J Neuroinflammation. 2012 May 29;9:106
pubmed: 22642825
Bioessays. 2009 Dec;31(12):1327-36
pubmed: 19921660
Birth Defects Res B Dev Reprod Toxicol. 2007 Jun;80(3):188-207
pubmed: 17570132
Oncogene. 2013 Sep 5;32(36):4191-202
pubmed: 23318436
Sci Rep. 2017 Jul 14;7(1):5377
pubmed: 28710481
Cell. 2005 Apr 8;121(1):141-52
pubmed: 15820685
FASEB J. 2017 Jan;31(1):172-179
pubmed: 27671228
FEBS J. 2009 Nov;276(22):6455-63
pubmed: 19804413
CNS Neurol Disord Drug Targets. 2011 May;10(3):391-403
pubmed: 21288189
J Cell Sci. 2015 Feb 1;128(3):541–52
pubmed: 25501810
Antioxid Redox Signal. 2016 Jul 10;25(2):61-77
pubmed: 27009601
J Biol Chem. 2016 Sep 23;291(39):20811-21
pubmed: 27528608
Curr Opin Neurobiol. 2000 Dec;10(6):790-5
pubmed: 11240291
Expert Opin Drug Saf. 2012 Jan;11(1):107-20
pubmed: 22066855
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5164-E5173
pubmed: 29760073
Biochem J. 2012 Aug 15;446(1):99-111
pubmed: 22612223
Bioorg Med Chem. 2018 May 1;26(8):1547-1559
pubmed: 29472124
Br J Haematol. 2020 Feb;188(4):501-510
pubmed: 31588567
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4820
pubmed: 24471177
Neurobiol Aging. 2015 Mar;36(3):1559-68
pubmed: 25660193
Mol Cell Biol. 2014 Jun;34(12):2147-61
pubmed: 24687852
Int J Mol Sci. 2019 Jan 24;20(3):
pubmed: 30682785
Acta Neuropathol Commun. 2015 Dec 14;3:84
pubmed: 26666562
Curr Alzheimer Res. 2017;14(4):403-411
pubmed: 28124585
Br J Pharmacol. 2018 Aug;175(16):3298-3314
pubmed: 29570770
Front Mol Neurosci. 2018 Apr 27;11:144
pubmed: 29755317
Expert Rev Anticancer Ther. 2014 May;14(5):499-510
pubmed: 24738833
J Neurochem. 2016 Oct;139 Suppl 1:59-74
pubmed: 27090875
Immunol Lett. 2016 Feb;170:42-51
pubmed: 26730849
J Cell Biol. 2009 Jul 13;186(1):129-45
pubmed: 19596851
J Neuroinflammation. 2016 Jun 28;13(1):168
pubmed: 27353053
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Exp Cell Res. 2008 Jun 10;314(10):2055-65
pubmed: 18445495
Lancet. 2009 Jun 13;373(9680):2055-66
pubmed: 19524782
J Neurosci. 2012 Feb 1;32(5):1602-11
pubmed: 22302802
Curr Alzheimer Res. 2007 Sep;4(4):378-85
pubmed: 17908040
Front Immunol. 2014 Sep 23;5:459
pubmed: 25295041
Prog Neurobiol. 2017 Aug;155:57-75
pubmed: 27107797
J Neuroinflammation. 2015 May 14;12:93
pubmed: 25966683
Blood. 2013 Jan 31;121(5):858
pubmed: 23372151

Auteurs

Maria Antonietta Casu (MA)

CNR Institute of Translational Pharmacology, Cagliari, Italy.

Ignazia Mocci (I)

CNR Institute of Translational Pharmacology, Cagliari, Italy.

Raffaella Isola (R)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Augusta Pisanu (A)

CNR Institute of Neuroscience, Cagliari, Italy.

Laura Boi (L)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Giovanna Mulas (G)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.

Nigel H Greig (NH)

National Institute of Aging (NIA), Drug Design & Development Section, Translational Gerontology Branch, Baltimore, MD, United States.

Maria Dolores Setzu (MD)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Anna R Carta (AR)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Classifications MeSH